Abstract:Cardiovascular diseases (CVDs) are complex, multifactorial conditions that require personalized assessment and treatment. Advancements in multi-omics technologies, namely RNA sequencing and whole-genome sequencing, have provided translational researchers with a comprehensive view of the human genome. The efficient synthesis and analysis of this data through integrated approach that characterizes genetic variants alongside expression patterns linked to emerging phenotypes, can reveal novel biomarkers and enable the segmentation of patient populations based on personalized risk factors. In this study, we present a cutting-edge methodology rooted in the integration of traditional bioinformatics, classical statistics, and multimodal machine learning techniques. Our approach has the potential to uncover the intricate mechanisms underlying CVD, enabling patient-specific risk and response profiling. We sourced transcriptomic expression data and single nucleotide polymorphisms (SNPs) from both CVD patients and healthy controls. By integrating these multi-omics datasets with clinical demographic information, we generated patient-specific profiles. Utilizing a robust feature selection approach, we identified a signature of 27 transcriptomic features and SNPs that are effective predictors of CVD. Differential expression analysis, combined with minimum redundancy maximum relevance feature selection, highlighted biomarkers that explain the disease phenotype. This approach prioritizes both biological relevance and efficiency in machine learning. We employed Combination Annotation Dependent Depletion scores and allele frequencies to identify variants with pathogenic characteristics in CVD patients. Classification models trained on this signature demonstrated high-accuracy predictions for CVD. The best performing of these models was an XGBoost classifier optimized via Bayesian hyperparameter tuning, which was able to correctly classify all patients in our test dataset. Using SHapley Additive exPlanations, we created risk assessments for patients, offering further contextualization of these predictions in a clinical setting. Across the cohort, RPL36AP37 and HBA1 were scored as the most important biomarkers for predicting CVDs. A comprehensive literature review revealed that a substantial portion of the diagnostic biomarkers identified have previously been associated with CVD. The framework we propose in this study is unbiased and generalizable to other diseases and disorders.

The Evaluation of Novel Biomarkers and the Multiple Biomarker Approach in the Prediction of Cardiovascular Disease

The Evaluation of Novel Biomarkers and the Multiple Biomarker Approach in the Prediction of Cardiovascular Disease

Circulating Biomarkers for Cardiovascular Disease Risk Prediction in Patients With Cardiovascular Disease

Do we really need more new biomarkers for cardiovascular risk prediction?

Aggregate Clinical and Biomarker-Based Model Predicts Adverse Outcomes in Patients With Coronary Artery Disease

Multiple Cardiac Biomarkers to Improve Prediction of Cardiovascular Events: Findings from the Generation Scotland Scottish Family Health Study

Comparative Value of Coronary Artery Calcium and Multiple Blood Biomarkers for Prognostication of Cardiovascular Events

Nontraditional Cardiovascular Biomarkers and Risk Factors: Rationale and Future Perspectives

Novel methodologies for biomarker discovery in atherosclerosis

Novel biomarkers with potential for cardiovascular risk reclassification

Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction

Multimodal AI/ML for discovering novel biomarkers and predicting disease using multi-omics profiles of patients with cardiovascular diseases

The role of cardiac biomarkers in cardiovascular disease risk assessment

Emerging Biomarkers for Early Detection of Cardiovascular Disease

Improving Cardiovascular Risk Prediction Through Machine Learning Modelling of Irregularly Repeated Electronic Health Records

The Biomarkers for Acute Myocardial Infarction and Heart Failure.

Role of Cardiac Biomarkers in Epidemiology and Risk Outcomes

Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease

Association of cardiac biomarkers with long-term cardiovascular events in a community cohort

Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event

Emerging Circulating Biomarkers for Enhanced Cardiovascular Risk Prediction